Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. The Company has proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Type
Subsidiary
Parent Company
Sanofi
HQ
Gent, BE
Founded
2001
Website
ablynx.com
Ablynx was founded in 2001 and is headquartered in Gent, BE
Report incorrect company information

Key People/Management at Ablynx

Edwin Moses

Edwin Moses

CEO
Johan Heylen

Johan Heylen

Chief Commercial Officer
Wim Ottevaere

Wim Ottevaere

CFO
Robert Friesen

Robert Friesen

Chief Scientific Officer
Piet Houwen

Piet Houwen

Chief Operations Officer
Guido Gielen

Guido Gielen

VP Human Resources
Show more

Ablynx Office Locations

Ablynx has offices in Conshohocken and Gent
Gent, BE (HQ)
21 Technologiepark-Zwijnaarde
Conshohocken, US
400 Eight Tower Bridge 161 Washington St
Show all (2)
Report incorrect company information

Ablynx Financials and Metrics

Summary Metrics

Founding Date

2001

Total Funding

$98.3 m
Ablynx is a subsidiary of Sanofi

Ablynx Revenue

Ablynx's revenue was reported to be €85.19 m in FY, 2016 which is a 9.9% increase from the previous period.
EURFY, 2015FY, 2016

Revenue

77.5 m85.2 m

Revenue growth, %

10%

General and administrative expense

11.4 m13.5 m

R&D expense

83.1 m100.3 m
Annual
EURFY, 2015FY, 2016

Cash

3.6 m53.4 m

Accounts Receivable

9.3 m4.8 m

Current Assets

246.1 m242.2 m

PP&E

2.6 m3.7 m
Quarterly
EURQ2, 2015Q2, 2016

Cash

53.4 m26.4 m

Accounts Receivable

4.8 m4.1 m

Current Assets

242.2 m210.5 m

PP&E

3.7 m3.9 m
Annual
EURFY, 2015FY, 2016

Net Income

(54.5 m)(1.1 m)

Depreciation and Amortization

1.1 m1.8 m

Accounts Payable

(45.2 m)(43.2 m)

Cash From Operating Activities

(69 m)(66.6 m)
Quarterly
EURQ2, 2016Q2, 2017

Net Income

22.8 m(25.3 m)

Depreciation and Amortization

885 k1.5 m

Accounts Payable

(21.4 m)(7.9 m)

Cash From Operating Activities

(17.2 m)(29.3 m)
Show all financial metrics

Ablynx Operating Metrics

Q2, 2017

Clinical Programs

45

Patents (US)

50

Patents (foreign)

180

Patents and Patent Applications

400
Show all operating metrics
Report incorrect company information

Ablynx Online and Social Media Presence

Embed Graph
Report incorrect company information

Ablynx News and Updates

VC-backed Albynx debuts U.S. IPO

Ablynx, a Belgian biopharmaceutical company, has raised $200 million for its U.S. IPO after pricing its 11.4 million shares at $17.50 per share. The stock began trading October 25, 2017 on the NASDAQ under the ticker symbol “ABLX.” BofA Merrill Lynch, J.P. Morgan and Jefferies are the lead underwrit…

VC-backed Ablynx files for IPO

Ablynx, a Belgian biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Ablynx, which currently trades on the Euronext Brussels, is planning on listing its U.S. stock on the NASDAQ under the ticker symbol ABLX…
Report incorrect company information

Ablynx Company Life and Culture

Report incorrect company information